Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB/IV non-small cell lung cancer

Trial Profile

Phase II study of vinflunine and cetuximab in the second line treatment of stage IIIB/IV non-small cell lung cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Vinflunine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2012 Actual patient number is 16 according to ClinicalTrials.gov.
    • 20 Jan 2012 Actual patient number is 16 according to ClinicalTrials.gov.
    • 20 Jan 2012 Planned end date 1 Nov 2009 added as reported by ClinicalTrials.gov..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top